Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $627,367 | $537,830 | $570,767 | $1,551,268 |
| - Cash | $110,761 | $27,632 | $19,927 | $124,660 |
| + Debt | $1,085 | $973 | $1,463 | $0 |
| Enterprise Value | $517,691 | $511,171 | $552,303 | $1,426,608 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$525 | -$529 | -$50 |
| % Margin | – | – | – | – |
| EBITDA | -$54,386 | -$82,233 | -$53,760 | -$39,768 |
| % Margin | – | – | – | – |
| Net Income | $0 | -$77,388 | -$50,062 | -$39,770 |
| % Margin | – | – | – | – |
| EPS Diluted | 0 | -2.3 | -2.04 | -2.19 |
| % Growth | 100% | -12.7% | 6.8% | – |
| Operating Cash Flow | -$51,117 | -$63,682 | -$47,362 | -$37,983 |
| Capital Expenditures | -$52 | -$221 | -$346 | -$198 |
| Free Cash Flow | -$51,169 | -$63,903 | -$47,708 | -$38,181 |